REDEFINING Liver Cancer Diagnostics with Metabolite Profiling

According to the American Cancer Society, there will be 33,190 new cases of primary liver cancer and intrahepatic bile duct cancer in the United States in 2014; about 23,000 people will die of these cancers. Globally, liver cancer is the most common form of cancer and the leading cause of cancer deaths. In 2014, an estimated 600,000 people worldwide will die of liver cancer. One of the reasons is that liver cancer is often detected in later stages. Current tests are often not sensitive enough to detect early stage liver cancer.

Matrix-Bio is currently developing a VeraMarker™ Liver Cancer Screening (LCS) test intended to detect liver cancer in its earliest stages when it is more treatable. Additionally, the test can be used as a surveillance test for high-risk patients with Hepatitis C or Hepatitis B with cirrhosis. Up to five percent of these patients develop liver cancer within a year. Current screening tests for liver cancer are not sufficiently reliable for early detection. In prospective clinical studies, Matrix-Bio’s LCS test exhibits more than 95 percent accuracy.


Register for updates on our liver cancer diagnostic tests using metabolite profiling.


300px-American_Cancer_Society_Logo.svg
Learn more about liver cancer
.